

## Monogenic and Syndromic Obesity

### Precision Panel



### Overview

The heritability of obesity is estimated between 40-70%, but the genetics of obesity for most individuals is complex and involves the interaction of multiple genes with the environment. There are however several syndromic and non-syndromic forms of obesity that are monogenic and oligogenic that provide insight into the underlying molecular control of food intake and the mechanisms that control ingestive behavior and satiety to regulate body weight. The mode of inheritance is typically autosomal dominant.

The Igenomix Monogenic and Syndromic Precision Panel can be used to make a directed and accurate differential diagnosis of obesity, ultimately leading to a better management and prognosis of the disease and its outcomes. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

### Indications

The Igenomix Monogenic and Syndromic Obesity Precision Panel is indicated for those patients with obesity with or without family history of obesity presenting with the following manifestations:

- Abnormal weight growth pattern
- Elevated body mass index
- Hypertension
- Type 2 diabetes
- Metabolic Syndrome

### Clinical Utility

The clinical utility of this panel is:

- The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.
- Early initiation of treatment with a multidisciplinary team for early pharmacologic therapy, surgical intervention, and/or dietary modifications to reduce comorbidities associated with obesity.
- Risk assessment of asymptomatic family members according to the mode of inheritance.

## Genes & Diseases

GENE	OMIM DISEASES	INHERITANCE*	% GENE COVERAGE (20X)	HGMD**
<b>ADCY3</b>	Body Mass Index Quantitative Trait Locus	AR	97.98%	7 of 7
<b>AFF4</b>	Chops Syndrome, Cognitive Impairment-Coarse Facies-Heart Defects-Obesity-Pulmonary Involvement-Short Stature-Skeletal Dysplasia Syndrome	AD	99.42%	6 of 6
<b>ALMS1</b>	Alstrom Syndrome	AR	99.92%	302 of 305
<b>ANOS1</b>	Hypogonadotropic hypogonadism, Kallmann syndrome	X,XR,G	96.86	-
<b>ARL6</b>	Bardet-Biedl Syndrome, Retinitis Pigmentosa	AD,AR,X,XR,G	100%	17 of 21
<b>ATRX</b>	Alpha-thalassemia myelodysplasia syndrome, Mental retardation, Carpenter-waziri syndrome, Chudley-lowry-hoar syndrome, Holmes-gang syndrome, Juberg-marsidi syndrome, Neuroendocrine tumor of stomach, Smith-fineman-myers syndrome	X,XR,XD,G	98.5	-
<b>BBIP1</b>	Bardet-Biedl Syndrome	AR	99.88%	1 of 1
<b>BBS1</b>	Bardet-Biedl Syndrome	AR	100%	102 of 105
<b>BBS10</b>	Bardet-Biedl Syndrome	AR	100%	114 of 114
<b>BBS12</b>	Bardet-Biedl Syndrome	AR	99.78%	61 of 61
<b>BBS2</b>	Bardet-Biedl Syndrome, Retinitis Pigmentosa	AR	100%	99 of 100
<b>BBS4</b>	Bardet-Biedl Syndrome	AR	100%	45 of 48
<b>BBS5</b>	Bardet-Biedl Syndrome	AR	99.80%	30 of 31
<b>BBS7</b>	Bardet-Biedl Syndrome	AR	100%	48 of 48
<b>BBS9</b>	Bardet-Biedl Syndrome	AR	99.56%	50 of 51
<b>BDNF</b>	Ondine syndrome, Wagr syndrome	-	99.96	7 of 7
<b>C8ORF37</b>	Bardet-Biedl Syndrome, Cone Rod Dystrophy, Retinitis Pigmentosa	AD,AR,X,XR,G	-	-
<b>CEP19</b>	Morbid Obesity And Spermatogenic Failure	AR	99.88%	2 of 2
<b>CEP290</b>	Bardet-Biedl Syndrome, Joubert Syndrome, Joubert Syndrome With Oculorenal Defect, Leber Congenital Amaurosis, Meckel Syndrome, Senior-Loken Syndrome	AR	96.47%	293 of 327
<b>CPE</b>	Hyperproinsulinemia, Gas Gangrene, Insulinoma, Diabetes Mellitus	-	96.28	0 of 1
<b>CREBBP</b>	Menke-hennekam syndrome, Rubinstein-taybi syndrome	AD	100	318 of 318
<b>CUL4B</b>	X-Linked Mental Retardation With Short Stature, Small Testes, Musclevasting, And Tremor, X-linked Intellectual Disability, Cabezas Type	X,XR,G	99.77%	-
<b>DYRK1B</b>	Abdominal Obesity-Metabolic Syndrome	AD	99.72%	3 of 3
<b>EHMT1</b>	Kleefstra syndrome	AD	98.58	58 of 75
<b>EP300</b>	Colorectal cancer, Menke-hennekam syndrome, Rubinstein-taybi syndrome	AD	100	109 of 109
<b>FGFR1</b>	Encephalocraniocutaneous lipomatosis, Hartsfield syndrome, Jackson-weiss syndrome, Kallmann syndrome, Osteoglophonic dysplasia, Pfeiffer syndrome, Trigenocephaly, Trigenocephaly, Holoprosencephaly, Hypogonadotropic hypogonadism, Oligodontia, Septo-optic dysplasia spectrum	AD	100	279 of 280
<b>FTO</b>	Body mass index quantitative trait locus, Growth retardation, developmental delay, coarse facies	AR	99.91	8 of 8
<b>GHRL</b>	Obesity	AD,AR,MU,P	100	1 of 1
<b>GNAS</b>	ACTH-Independent Macronodular Adrenal Hyperplasia, Albright Hereditary Osteodystrophy, Cushing Syndrome, Mazabraud Syndrome, McCune-Albright Syndrome, Progressive Osseous Heteroplasia, Pseudohypoparathyroidism Type 1A Pseudohypoparathyroidism Type 1B, Pseudohypoparathyroidism Type 1C, Pseudopseudohypoparathyroidism	AD	99.95%	263 of 273
<b>IFT172</b>	Bardet-Biedl Syndrome, Jeune Syndrome, Retinitis Pigmentosa, Short-Rib Thoracic Dysplasia	AR	100%	37 of 37




<b>IFT27</b>	Bardet-Biedl Syndrome	AR	100%	5 of 5
<b>IFT74</b>	Bardet-Biedl Syndrome	AR	99.95%	6 of 6
<b>INPP5E</b>	Joubert syndrome, Mental retardation, truncal obesity, retinal dystrophy	AR	99.89	56 of 56
<b>INS</b>	Diabetes mellitus, Hyperproinsulinemia	AD,AR	100	78 of 84
<b>INSR</b>	Donohue syndrome, Hyperinsulinemic hypoglycemia, Pineal hyperplasia, Leprechaunism, Rabson-mendenhall syndrome	AD,AR	98.03	181 of 184
<b>KDM6A</b>	Kabuki syndrome	AD,X,XD,G	99.98	-
<b>KIDINS220</b>	Spastic Paraplegia-Intellectual Disability-Nystagmus-Obesity Syndrome	AD	99.83%	17 of 17
<b>KMT2D</b>	Kabuki syndrome	AD	99.71	839 of 847
<b>KSR2</b>	Obesity, Insulin Resistance and Impaired Cellular Fuel Oxidation	-	99.88%	29 of 29
<b>LEP</b>	Leptin Deficiency Or Dysfunction	AR	100%	19 of 19
<b>LEPR</b>	Leptin Receptor Deficiency	AR	97.92%	49 of 49
<b>LZTFL1</b>	Bardet-Biedl Syndrome	AR	99.83%	4 of 4
<b>MAGEL2</b>	MAGEL2-related Prader-Willi-Like Syndrome, Prader-Willi Syndrome	AD	99.99%	43 of 48
<b>MC3R</b>	Body mass index quantitative trait locus	-	100	20 of 20
<b>MC4R</b>	Body Mass Index Quantitative Trait Locus, Obesity Due To Melanocortin 4 Receptor Deficiency	AD,AR	100%	165 of 166
<b>MEGF8</b>	Carpenter syndrome	AR	98.97	22 of 22
<b>MKKS</b>	Bardet-Biedl Syndrome, Mckusick-Kaufman Syndrome	AR	89.96%	71 of 71
<b>MKS1</b>	Bardet-Biedl Syndrome, Joubert Syndrome, Joubert Syndrome With Ocular Defect, Meckel Syndrome	AR	99.98%	49 of 49
<b>MYT1L</b>	Autosomal Dominant Mental Retardation, MRD39 chromosome 2p25.3 Deletion Syndrome	AD	99.98%	30 of 30
<b>NR0B2</b>	Obesity	AD,AR,MU,P	99.09%	15 of 15
<b>NTRK2</b>	Early Infantile Epileptic Encephalopathy, Obesity, Hyperphagia, And Developmental Delay, Undetermined Early-onset Epileptic Encephalopathy, West Syndrome	AD	100%	9 of 9
<b>PCNT</b>	Microcephalic osteodysplastic primordial dwarfism, Seckel syndrome	AR	99.92	103 of 105
<b>PCSK1</b>	Obesity Due To Prohormone Convertase I Deficiency, Proprotein Convertase 1 Deficiency	AR	99.98%	45 of 45
<b>PHF6</b>	Borjeson-Forssman-Lehmann Syndrome	X,XR,G	99.93%	-
<b>PHIP</b>	Developmental Delay, Intellectual Disability, Obesity, And Dysmorphic Features	AD	98.74%	51 of 52
<b>POMC</b>	Obesity Due To Pro-Opiomelanocortin Deficiency	AD,AR,MU,P	99.98%	40 of 40
<b>PPARG</b>	Berardinelli-Seip Congenital Lipodystrophy, Carotid Intimal Medial Thickness, Noninsulin-Dependent Diabetes Mellitus, Familial Partial Lipodystrophy, Obesity, PPARG-related Familial Partial Lipodystrophy	AD,AR,MU,P	99.94%	53 of 53
<b>PPARGC1B</b>	Carotid intimal medial thickness, Diabetes mellitus, Lipodystrophy, Obesity, Berardinelli-seip congenital lipodystrophy	-	99.98	6 of 6
<b>PRMT7</b>	Short Stature-Brachydactyly-Obesity-Global Developmental Delay Syndrome	AR	100%	13 of 14
<b>PROK2</b>	Hypogonadotropic hypogonadism, Kallmann syndrome	AD	100	20 of 20
<b>PROKR2</b>	Hypogonadotropic hypogonadism, Kallmann syndrome, Pituitary stalk interruption syndrome, Septo-optic dysplasia spectrum	AD	100	64 of 64
<b>PYY</b>	Eating Disorder, Short Bowel Syndrome, Dumping Syndrome	-	99.99	-
<b>RAB23</b>	Carpenter syndrome	AR	100	15 of 15
<b>RAI1</b>	17p11.2 Microduplication Syndrome, PMP22-RAI1 Contiguous Gene Duplication Syndrome, Smith-Magenis Syndrome	AD	99.91%	50 of 53
<b>RPS6KA3</b>	Coffin-lowry syndrome, Mental retardation	X,XD,G	99.95	-
<b>SDCCAG8</b>	Bardet-Biedl Syndrome, Senior-Loken Syndrome	AR	96.29%	18 of 19
<b>SETD2</b>	Luscan-Lumish Syndrome, Sotos Syndrome	AD	99.83%	19 of 19

<b>SH2B1</b>	Distal 16p11.2 Microdeletion Syndrome, Proximal 16p11.2 Microdeletion Syndrome, Severe Early-Onset Obesity-Insulin Resistance Syndrome Due To Sh2b1 Deficiency	-	99.98%	25 of 25
<b>SIM1</b>	6q16 Microdeletion Syndrome, Obesity Due To SIM1 Deficiency, SIM1-Related Prader-Willi-Like Syndrome	-	99.64%	39 of 40
<b>SOX10</b>	Waardenburg syndrome, Kallmann syndrome, Peripheral demyelinating neuropathy, Dysmyelinating leukodystrophy, hirschsprung disease	AD	99.74	139 of 147
<b>TBX3</b>	Ulnar-mammary syndrome	AD	99.95	27 of 28
<b>TMEM67</b>	Bardet-biedl syndrome, Coach syndrome, Joubert syndrome, Meckel syndrome, Nephronophthisis, Rhyns syndrome	AR	96.93	177 of 179
<b>TRIM32</b>	Bardet-Biedl Syndrome, Limb-Girdle Muscular Dystrophy Type 2H, TRIM32-Related Limb-Girdle Muscular Dystrophy	AR	100%	17 of 17
<b>TTC8</b>	Bardet-Biedl Syndrome, Retinitis Pigmentosa	AR	99.33%	28 of 28
<b>TUB</b>	Retinal dystrophy, obesity, Retinitis pigmentosa	AR	99.91	4 of 4
<b>UBE2A</b>	Mental retardation	X,XR,G	99.99	-
<b>UCP1</b>	Lipomatosis, Diabetes Mellitus	-	100	2 of 2
<b>UCP2</b>	Hyperinsulinism	-	100	7 of 7
<b>UCP3</b>	Obesity	AD,AR,MU,P	99.98%	6 of 6
<b>VPS13B</b>	Cohen Syndrome	AR	99.98%	182 of 190
<b>WDPCP</b>	Bardet-Biedl Syndrome, Congenital Heart Defects, Hamartomas Of Tongue, And Polysyndactyly, Meckel Syndrome	AR	99.30%	8 of 8

\*Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial.

\*\*Number of clinically relevant mutations according to HGMD

## Methodology



**Contact us**

Call +34 963 905 310 or send an email to [supportspain@igenomix.com](mailto:supportspain@igenomix.com) for any of the following objectives:

- Get more information about the test.
- Request your kit.
- Request a pick up of the kit after collecting the sample.

## References

1. Rohde, K., Keller, M., la Cour Poulsen, L., Blüher, M., Kovacs, P., & Böttcher, Y. (2019). Genetics and epigenetics in obesity. *Metabolism: clinical and experimental*, 92, 37–50. <https://doi.org/10.1016/j.metabol.2018.10.007>
2. Reddon, H., Guéant, J. L., & Meyre, D. (2016). The importance of gene-environment interactions in human obesity. *Clinical science (London, England : 1979)*, 130(18), 1571–1597. <https://doi.org/10.1042/CS20160221>
3. Kleinberger, J. W., Copeland, K. C., Gandica, R. G., Haymond, M. W., Levitsky, L. L., Linder, B., Shuldiner, A. R., Tollefsen, S., White, N. H., & Pollin, T. I. (2018). Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. *Genetics in medicine : official journal of the American College of Medical Genetics*, 20(6), 583–590. <https://doi.org/10.1038/gim.2017.150>